Contact Us
  • This field is for validation purposes and should be left unchanged.

National Center for Advancing Translational Sciences (NCATS)

A. Innovative platforms for identification and prioritization of targets for therapeutic intervention with clear clinical impact
B. Technologies to determine alternative uses for existing therapeutic interventions
C. Tools and technologies to allow assaying of activities of compounds on currently ?non-druggable? targets
D. Phenotypic assay development, including stem cell technology platforms for human ?disease in a dish? applications and the evaluation of toxicity
E. Co-crystallization high-throughput screening techniques
F. Small molecule and biologics analytical characterization
G. Tools and technologies that increase the predictivity or efficiency of medicinal chemistry, biologic, or other intervention optimization
H. Accelerate bioengineering approaches to the development and clinical application of biomedical materials, devices, therapeutics, and/or diagnostics
I. Tools and technologies that increase the efficiency of human subjects research, including development of technologies that facilitate rapid diagnosis and/or clinical trial recruitment and subject tracking, IRB evaluation, and/or regulatory processes
J. Novel platforms, technologies and tools to enable clinical and translational research, particularly those with mechanisms for inclusion of patient reported data
K. Searchable access to information about researchers and their expertise, including but not limited to their publications, published data sets, methods, patents, clinical trials, partnerships, collaborators, and clinical specialty/expertise (if applicable)
L. Tools for meaningful sharing of research data with low barrier for provision and user friendly access
M. Searchable access to information about research resources, facilities, methods, cells, genetic tests, molecules, biologic reagents, animals, assays, technologies with links to their use in published research studies

Contact Us
  • This field is for validation purposes and should be left unchanged.